HIF1A and glioblastoma: Also, in vivo and pilot clinical studies have reported HIF-1α or VEGF immunophenotypes fitted with the correlation of PET-imaging [82] and/or MRI [85–88], supporting the combined macroscopic evaluation with histopathological features in monitoring [88] and distinguishing GBM tumor progression from pseudoprogression [89] (Fig. 2).